MPYS protein stimulants - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “MPYS protein stimulants - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in MPYS protein stimulants pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
MPYS protein stimulants: Overview
Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173) and MPYS/MITA/ERIS is a protein that in humans is encoded by the STING1 gene. STING plays an important role in innate immunity. STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. Type I interferon, mediated by STING, protects infected cells and nearby cells from local infection by binding to the same cell that secretes it (autocrine signaling) and nearby cells (paracrine signaling.) It thus plays an important role, for instance, in controlling norovirus infection.
Report Highlights
This segment of the MPYS protein stimulants report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MPYS protein stimulants Emerging Drugs
Further product details are provided in the report……..
MPYS protein stimulants: Therapeutic Assessment
This segment of the report provides insights about the different MPYS protein stimulants drugs segregated based on following parameters that define the scope of the report, such as:
MPYS protein stimulants: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MPYS protein stimulants therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MPYS protein stimulants drugs.
MPYS protein stimulants Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “MPYS protein stimulants - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in MPYS protein stimulants pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
MPYS protein stimulants: Overview
Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173) and MPYS/MITA/ERIS is a protein that in humans is encoded by the STING1 gene. STING plays an important role in innate immunity. STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. Type I interferon, mediated by STING, protects infected cells and nearby cells from local infection by binding to the same cell that secretes it (autocrine signaling) and nearby cells (paracrine signaling.) It thus plays an important role, for instance, in controlling norovirus infection.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence MPYS protein stimulants R&D. The therapies under development are focused on novel approaches for MPYS protein stimulants.
This segment of the MPYS protein stimulants report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MPYS protein stimulants Emerging Drugs
- MK 1454: Merck & Co
- SYNB1891: Synlogic
Further product details are provided in the report……..
MPYS protein stimulants: Therapeutic Assessment
This segment of the report provides insights about the different MPYS protein stimulants drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on MPYS protein stimulants
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
MPYS protein stimulants: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MPYS protein stimulants therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MPYS protein stimulants drugs.
MPYS protein stimulants Report Insights
- MPYS protein stimulants Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing MPYS protein stimulants drugs?
- How many MPYS protein stimulants drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MPYS protein stimulants?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MPYS protein stimulants therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for MPYS protein stimulants and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck & Co
- Synlogic
- Chinook Therapeutics
- Takeda
- Codiak BioSciences
- ImmuneSensor
- Shanghai De Novo Pharmatech
- OncoNano Medicine
- Eternity Bioscience
- X-37
- F-star Therapeutics
- Mavupharma
- Bristol-Myers Squibb
- GlaxoSmithKline
- LIDDS
- Trillium Therapeutics Inc
- Silicon Therapeutics
- Mersana Therapeutics
- Actym Therapeutics
- Stimunity
- Curadev Pharma
- MK 1454
- SYNB1891
- TTI 10001
- SNX-281
- ADU S100
- STACT-TREX1
- NZ-IO-STING
- TAK 676
- GSK 532
- BMS 986301
- CRD 5500
- exoSTING
- IMSA 101
- MAVU 104
- DN 015089
- SB 11312
- Research programme: cGAS/STING agonists
- ONM 501
- TAK 500
- ONM 500
- Non-CDN STING agonist
Introduction
Executive Summary
MPYS protein stimulants: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
MPYS protein stimulants – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MK 1454: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
SYNB1891: Synlogic
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TAK 500: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
MPYS protein stimulants Key Companies
MPYS protein stimulants Key Products
MPYS protein stimulants- Unmet Needs
MPYS protein stimulants- Market Drivers and Barriers
MPYS protein stimulants- Future Perspectives and Conclusion
MPYS protein stimulants Analyst Views
MPYS protein stimulants Key Companies
Appendix
Executive Summary
MPYS protein stimulants: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
MPYS protein stimulants – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MK 1454: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
SYNB1891: Synlogic
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TAK 500: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
MPYS protein stimulants Key Companies
MPYS protein stimulants Key Products
MPYS protein stimulants- Unmet Needs
MPYS protein stimulants- Market Drivers and Barriers
MPYS protein stimulants- Future Perspectives and Conclusion
MPYS protein stimulants Analyst Views
MPYS protein stimulants Key Companies
Appendix